X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Lilly gains control of the partnered encapsulated cell therapies, including SIG-002 (human insulin), for the treatment of type 1 diabetes.
Lead Product(s): SIG-002
Therapeutic Area: Endocrinology Product Name: SIG-002
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $344.2 million Upfront Cash: $344.2 million
Deal Type: Acquisition August 14, 2023
Details:
Through the acquisition, Lilly will gain control of the partnered encapsulated cell therapies, including SIG-002 (human insulin), for the treatment of type 1 diabetes.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Product Name: SIG-002
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $344.2 million Upfront Cash: $344.2 million
Deal Type: Acquisition June 29, 2023
Details:
SIG-005 contains a human cell line genetically modified with a non-viral vector designed to express human a-L-iduronidase (IDUA), an enzyme which is missing or defective in patients with MPS-1.
Lead Product(s): SIG-005
Therapeutic Area: Genetic Disease Product Name: SIG-005
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2022
Details:
Sigilon recently filed a Clinical Trial Application (CTA) in the United Kingdom for SIG-005 in MPS-1 and anticipates submitting an Investigational New Drug (IND) application and a CTA in the United States and Brazil, respectively.
Lead Product(s): SIG-005
Therapeutic Area: Genetic Disease Product Name: SIG-005
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2021
Details:
SIG-005 contains a human cell line genetically modified with a non-viral vector designed to express human a-L-iduronidase (IDUA), an enzyme which is missing or defective in patients with MPS-1.
Lead Product(s): SIG-005
Therapeutic Area: Genetic Disease Product Name: SIG-005
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2020
Details:
Sigilon's lead candidate, SIG-001, is designed to prevent bleeding episodes in patients with Hemophilia A and recently began a Phase 1/2 trial.
Lead Product(s): SIG-001
Therapeutic Area: Genetic Disease Product Name: SIG-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 13, 2020
Details:
The funding will support the first-in-human clinical trial of Sigilon’s novel encapsulated cell therapy for hemophilia A.
Lead Product(s): SIG-001
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Canada Pension Plan Investment Board
Deal Size: $80.3 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
